White label – Pompe disease - ClinicalTrials.eu

Study comparing QL2107 and pembrolizumab in patients with resected non-small cell lung cancer receiving adjuvant therapy

Recruiting

3 1 1 1
Investigated Diseases:
- Non-small cell lung cancer
Investigated Drugs:
- Pembrolizumab
Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Recruiting

3 1 1 1
Investigated Drugs:
- Cemiplimab
+1
Evaluation of controlled-ileal-release nicotinic acid tablets compared to placebo for treating people with prediabetes

Recruiting

2 1
Study of evenamide as add-on treatment for patients with treatment-resistant schizophrenia not adequately controlled by current antipsychotic medications

Recruiting

3 1

+3
Study of psilocybin compared to personalized rTMS treatment in adults with treatment-resistant depression

Recruiting

2 1
Investigated Diseases:
- Depression
Investigated Drugs:
- Dry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol
Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Recruiting

3 1 1 1
Investigated Drugs:
+10
Long-term safety and effectiveness study of APG777 injection in patients with moderate-to-severe atopic dermatitis who previously received APG777 treatment

Recruiting

2 1
Investigated Diseases:
- Dermatitis atopic
Investigated Drugs:
- Apg777
Comparison of Gentamicin with Narrow-Spectrum Antibiotics versus Broad-Spectrum Antibiotics in Adult Patients with Early Sepsis

Recruiting

3 1 1 1
Investigated Drugs:
Study of BMS-986504 for patients with advanced or metastatic non-small cell lung cancer with homozygous MTAP deletion who have previously received treatment

Recruiting

2 1 1
Investigated Drugs:
- 2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE
+1
Study of elacestrant and exemestane treatment for patients with previously treated hormone receptor-positive, HER2-negative metastatic breast cancer with FES-avid lesions

Recruiting

2 1 1 1
Investigated Diseases:
- Breast cancer metastatic
- Hormone receptor positive HER2 negative breast cancer
Investigated Drugs:

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies